Mankind Pharma eyes 50% revenue from chronic therapy drugs in 3 years

With the launch, the company has become the first Indian and second global firm to develop the drug, which is a generic version of Abbott's Duphaston

Mankind Pharmaceuticals, a key player in acute therapies, has sharpened its focus on chronic therapy drugs (like anti-diabetics and cardiac) and is eyeing 50 per cent revenue from this segment in three years.
 
In fact, it recently applied to drugs regulator Drugs Controller General of India (DCGI), seeking approval to start phase 1 human trials of its novel anti-diabetes drug, which has completed animal trials. The compound annual growth rate (CAGR) in the chronic portfolio is 30 per cent and the category contributes around 25-30 per cent of overall revenues. The Rs 6,500-crore privately held firm is eyeing a